Peptide therapy isn't new. The uncertainty around it is real.
Peptide medicine has existed for over a century — insulin itself is a peptide, and it's one of the most-studied drugs in history. What's different about many of today's longevity and performance peptides is that, unlike most medications your physician prescribes, they've never been tested in a randomized controlled human trial. Most of what we know comes from cell-culture and animal research. At Metronome, that gap is something we talk through openly — not something we gloss over to make a sale.
Amino Acid, Peptide, Protein — What's Actually the Difference?
The word "peptide" gets used constantly in the wellness world, often without much explanation. It's simpler than the marketing makes it sound.
Amino Acid
The roughly 20 small molecules your body uses as raw material to build everything from muscle to hormones to enzymes. Think of them as individual letters.
Peptide
A short chain of amino acids — usually somewhere from 2 to about 50 — linked together. Short enough to be simple and specific, often acting like a precise biological signal.
Protein
A much longer chain of amino acids that folds into a complex 3D structure — collagen, antibodies, and enzymes are all proteins built from the same basic letters.
Two Peptides You Already Trust
"Peptide" describes a type of molecule — not a level of evidence. Some peptides are among the most rigorously studied medications that exist.
Insulin
A 51-amino-acid peptide hormone. Over a century of use and thousands of clinical trials make it one of the best-understood medications in existence.
GLP-1 Medications
Semaglutide and tirzepatide are peptide analogs of a natural gut hormone. Their approval rests on large, randomized, placebo-controlled human trials — the same standard most other prescription drugs are held to.
The real question for any specific peptide isn't "is it a peptide?" — it's "how much human trial evidence exists for this exact use, in people like you?" That answer varies enormously from one peptide to the next.
When the Evidence Is Real — But Narrower Than It Sounds
Some peptides used in longevity and performance circles do have genuine human trial data. The nuance patients rarely hear: what they were studied for often isn't the same as how they're being used today.
Tesamorelin
FDA-approved in 2010 based on real Phase 3 randomized, placebo-controlled trials — but specifically for reducing visceral abdominal fat in HIV-associated lipodystrophy, showing roughly 15–18% reductions over 26 weeks.
What the trials didn't establish: long-term cardiovascular safety, or the effects of sustained elevated IGF-1 levels. Off-label use for general body composition or longevity borrows evidence gathered in a very different patient population, for a different question.
Growth Hormone Secretagogues
Sermorelin has real clinical trial history and FDA approval — specifically for diagnosing and treating growth hormone deficiency in children. It was discontinued in 2008 for manufacturing reasons, not safety.
Newer analogs marketed for adult longevity (ipamorelin and related peptides) mostly rest on short-term pharmacology data. Long-term safety and efficacy in healthy adults — the population actually using them today — remains largely unstudied.
Most of the Buzz Rests on Cell Cultures and Mice — Not People
Beyond the peptides with at least some human trial history, much of what circulates in the wellness and longevity space — BPC-157, TB-500, epitalon, and others — is supported mainly by in vitro and animal research. That's legitimate early-stage science, but it's a different tier of evidence than a completed human trial, and the gap between "worked in a petri dish" and "works in you" is where most promising compounds quietly fail.
Social media has amplified enthusiasm for these compounds faster than the research has caught up, and the information landscape is genuinely mixed — credible clinical nuance sits right alongside confident overstatement. It's understandable that most conventionally trained physicians are uncomfortable prescribing into that much uncertainty.
Medicine Trains Physicians, Above All, to Keep Learning
Patient interest in peptide therapy is only growing, and it deserves a real conversation rather than a shrug or a sales pitch. As select peptides move toward more regulated access through US compounding pharmacies, having a physician who already knows your full health picture — and is willing to engage honestly with emerging evidence — is worth more than a specialist who sees only one narrow slice of you.
Whole-Picture Context
Your hormones, metabolic health, and medication history all live with one physician — not scattered across a peptide clinic that's never seen your labs.
Honest Risk/Benefit Conversation
A candid discussion of what's actually been studied, what hasn't, and what that uncertainty means for you specifically — not a script.
Navigating a Shifting Landscape
Regulatory status, sourcing, and quality vary peptide by peptide and are actively changing. Metronome helps you make sense of it as it evolves.
Related Care at Metronome
Curious about peptide therapy? Let's actually talk it through.
Schedule a consultation for an honest conversation about whether an emerging therapy fits your health picture — evidence, uncertainty, and all.